DELPACIBART ZOTADIRSEN
UNII LGW2VY8NTG

Substance Identification & Data

This profile provides standardized clinical and technical data for Delpacibart Zotadirsen, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LGW2VY8NTG.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2929240-20-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LGW2VY8NTG

CAS Registry Number

2929240-20-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DELPACIBART ZOTADIRSEN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211784

National Cancer Institute reference terminology for clinical and research data.

INN ID

13250

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-203

Identifier assigned by the United States Adopted Names Council.

Substance Type

Delpacibart Zotadirsen

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Delpacibart Zotadirsen. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Delpacibart Zotadirsen

Common Names & Synonyms

DELPACIBART ZOTADIRSEN [USAN]

Delpacibart 44DMD01 conjugate

H-gamma1 heavy chain humanized (1-445) [VH (Homo sapiens IGHV1-2*06 (87.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116) -Homo sapiens IGHG1*03,G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v14 CH2 A1.3, A1.2, G1v48 CH2R113 (CH1 R120 (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234), L113>R (327) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-214)-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-NL1*01 (84.2%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (225-225'': 228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;substituted at the sulfur atom of an average of four cysteine residues among 219, 225, 288, 214', 219'', 225'', 228'' and 214''' with a group consisting of all-Pambo-( 3RS)-1-({cis- and/or trans-4-[(3-{[2',3'-azanediyl-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-seco](2'-N→5')(C-G-C-C-G-C-C-A-m5Um5U-m5U-C-m5U-C-A-A-C-A-G-A-m5U-C-m5UG-m5U-C)-N2'.26-yl}-3-oxopropyl)carbamoyl]cyclohexyl}methyl)-2,5-dioxopyrrolidin-3-yl (zotadirsen)

Immunoglobulin G1 [233-alanine,234-alanine,327-arginine,de-446-lysine], anti-(human transferrin receptor 1) (human-Mus musculus monoclonal AV01 γ1-chain), disulfide with human-Mus musculus monoclonal AV01 κ-chain, dimer, reduced, thioether with RNA [P-deoxy-P-(dimethylamino)](2′,3′-dideoxy-2′,3′-imino-2′,3′-seco)(2′a→5′)(C-G-C-C-G-C-C-A-m5U-m5U-m5U-C-m5U-C-A-A-C-A-G-A-m5U-C-m5U-G-m5U-[2′a-[3-[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]-1-oxopropyl]]C)

Immunoglobulin G1-kappa, anti-[Homo sapiens TFRC (transferrin receptor, TfR1, TFR1, CD71)], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues via a 4-(maleimidomethyl)cyclohexanecarboxamide linker to a single-stranded oligonucleotide (zotadirsen); H-gamma1 heavy chain humanized (1-445) [VH (Homo sapiens IGHV1-2*06 (87.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116) -Homo sapiens IGHG1*03,G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v14 CH2 A1.3, A1.2, G1v48 CH2R113 (CH1 R120 (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234), L113>R (327) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-214)-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-NL1*01 (84.2%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (225-225'': 228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;substituted at the sulfur atom of an average of four cysteine residues among 219, 225, 288, 214', 219'', 225'', 228'' and 214''' with a group consisting of all-P-ambo-(3RS)-1-({cis- and/or trans-4-[(3-{[2',3'-azanediyl-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-seco](2'-N→5')(C-G-C-C-G-C-C-A-m5U-m5U-m5U-C-m5U-C-A-A-C-A-G-A-m5U-C-m5U-G-m5U-C)-N2'.26-yl}-3-oxopropyl)carbamoyl]cyclohexyl}methyl)-2,5-dioxopyrrolidin-3-yl (zotadirsen)

delpacibart zotadirsen [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens TFRC (transferrin receptor, TfR1, TFR1, CD71)], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues via a 4-(maleimidomethyl)cyclohexanecarboxamide linker to a single-stranded oligonucleotide (zotadirsen)